Chembio's POC Lyme Disease Assay Has Specificity Similar To Lab Tests
This article was originally published in The Gray Sheet
Executive SummaryClinical studies of Chembio Diagnostic Systems' PreVue B. burgdorferi antibody detection assay showed a specificity for the rapid point-of-care test similar to that for currently available laboratory diagnostics for Lyme disease.
You may also be interested in...
Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex
T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
How do the EU’s new MDR cybersecurity guidelines expand on the MDR and fit into the myriad other software-related guidance documents the medtech industry has to consider?